Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

201394 citationsJournal Articlegold Open Access

Authors

Moshe Talpaz · University of Michigan–Ann Arbor

Ronald Paquette · University of California, Los Angeles

Lawrence B. Afrin · Medical University of South Carolina

Solomon I. Hamburg · Tower Cancer Research Foundation

Josef T. Prchal · University of Utah

Katarzyna Jamieson · University of Iowa

Howard R. Terebelo

Abstract

Results suggest that a low starting dose of ruxolitinib with escalation to 10 mg BID may be appropriate in myelofibrosis patients with low platelet counts.

Topics & Keywords

Myeloproliferative Neoplasms: Diagnosis and Treatment Kruppel-like factors research Hemoglobinopathies and Related Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Hematology & Oncology

Volume 6, Issue 1, pp. 81-81

DOI: 10.1186/1756-8722-6-81

Field-Weighted Citation Impact: 6.92